In an interview with PharmaShots, Jonathan Benjamin, MD, Ph.D., Senior Vice President & Clinical Research of Atreca shared his views on the initial data from the dose-escalation portion of its ongoing P-Ib trial for ATRC-101 to treat solid tumorShots:The ongoing P-Ib trial evaluates ATRC-101 in patients with solid tumors & 26 patients had been dosed in a trial as of data cut-off…
